Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Recently, radiolabelled antagonists targeting somatostatin receptors subtype 2 (SST2) in neuroendocrine neoplasms demonstrated certain superior properties over agonists. Within the ERA-PerMED project “TECANT” two (99m)Tc-Tetramine (N4)-derivatized SST2 antagonists (TECANT-1 and TECANT-2) were studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Fani, Melpomeni, Weingaertner, Viktoria, Kolenc Peitl, Petra, Mansi, Rosalba, Gaonkar, Raghuvir H., Garnuszek, Piotr, Mikolajczak, Renata, Novak, Doroteja, Simoncic, Urban, Hubalewska-Dydejczyk, Alicja, Rangger, Christine, Kaeopookum, Piriya, Decristoforo, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824897/
https://www.ncbi.nlm.nih.gov/pubmed/33379299
http://dx.doi.org/10.3390/ph14010019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824897/
https://www.ncbi.nlm.nih.gov/pubmed/33379299
http://dx.doi.org/10.3390/ph14010019

Ejemplares similares